The state of the art in the development of a panel of biomarkers for the early detection of lung cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Thoracic Disease

• Publication date

  2018-01-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.21037/jtd.2018.01.03PMID 29608181PMCID PMC5864595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis

  2017cited by this paper
• Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer

  2017cited by this paper
• Non-small Cell Lung Cancer

  2016cited by this paper
• Non-small-cell lung cancer

  2015cited by this paper
• Prognostic role of serum p53 antibodies in lung cancer

  2015cited by this paper
• Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status

  2015cited by this paper
• Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis

  2014cited by this paper
• Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

  2013cited by this paper
• Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis.

  2012cited by this paper
• Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis.

  2011cited by this paper
• Autoantibodies in cancer: prognostic biomarkers and immune activation

  2011cited by this paper
• Complement Factor H Autoantibodies Are Associated with Early Stage NSCLC

  2010cited by this paper
• 非小细胞肺癌患者中Survivin抗体的临床意义及诊断价值

  2010cited by this paper
• Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer

  2010cited by this paper
• Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers

  2010influential reference
• Anti-survivin antibody responses in lung cancer.

  2009cited by this paper
• Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer

  2009cited by this paper
• Toward an early diagnosis of lung cancer: An autoantibody signature for squamous cell lung carcinoma

  2008cited by this paper
• Autoantibodies in lung cancer: possibilities for early detection and subsequent cure

  2007influential reference
• Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation

  2005cited by this paper
• Detection of anti-livin antibody in gastrointestinal cancer patients.

  2001cited by this paper
• An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer

  2001cited by this paper
• Detection of anti-survivin antibody in gastrointestinal cancer patients.

  2001cited by this paper
• Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.

  2000cited by this paper
• Serum p53 antibodies as early markers of lung cancer

  1995cited by this paper
• Cancer statistics

  1989cited by this paper

• EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.

  2022cites this paper
• Lung-Resident Mesenchymal Stem Cell Fates within Lung Cancer

  2021cites this paper
• Relationship between Serum Bilirubin Level and the Prevalence of Lung Cancer in Smokers

  2020cites this paper